Eton Pharmaceuticals Raises 2026 Revenue Guidance After Third-Quarter Results
Eton reported third-quarter revenue of $57.9 million versus $22.5 million a year earlier, GAAP diluted EPS of $1.06 and an Adjusted EBITDA margin of 49%. It raised 2026 revenue guidance to more than $175 million and margin guidance to more than 40%.
Eton Pharmaceuticals announced record financial results for the third quarter ended September 30, 2026, with net revenue of $57.9 million compared to $22.5 million in the prior-year period. This 158% growth was driven by the addition of HEMANGEOL revenue and increased sales across its portfolio, including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA, and Carglumic Acid. The company reported a GAAP fully diluted EPS of $1.06 and an Adjusted EBITDA margin of 49%. Eton also raised its 2026 revenue guidance to more than $175 million and its Adjusted EBITDA margin guidance to more than 40%.
Management noted that the company has surpassed its $200 million annualized revenue run rate goal five quarters ahead of schedule.